HBV Treatment
EASL: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
EASL: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
EASL: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL International Liver Congress Starts This Week in Barcelona
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.
Web Design and Development by